CA1050426A - Procede de production d'un compose pharmaceutique d'insuline utilise par voie rectale - Google Patents

Procede de production d'un compose pharmaceutique d'insuline utilise par voie rectale

Info

Publication number
CA1050426A
CA1050426A CA261,342A CA261342A CA1050426A CA 1050426 A CA1050426 A CA 1050426A CA 261342 A CA261342 A CA 261342A CA 1050426 A CA1050426 A CA 1050426A
Authority
CA
Canada
Prior art keywords
insulin
ether
polyoxyethylene
poe
surface active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA261,342A
Other languages
English (en)
Inventor
Hiroitsu Kawada
Hiroo Maeno
Shigeo Kawamura
Isao Ohata
Kunihide Ichikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP50116028A external-priority patent/JPS5241210A/ja
Priority claimed from JP50117810A external-priority patent/JPS5244222A/ja
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of CA1050426A publication Critical patent/CA1050426A/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA261,342A 1975-09-26 1976-09-16 Procede de production d'un compose pharmaceutique d'insuline utilise par voie rectale Expired CA1050426A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP50116028A JPS5241210A (en) 1975-09-26 1975-09-26 Method of making insulin preparations for rectal administration
JP50117810A JPS5244222A (en) 1975-09-30 1975-09-30 Method of making insulin preparations for rectal application

Publications (1)

Publication Number Publication Date
CA1050426A true CA1050426A (fr) 1979-03-13

Family

ID=26454417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA261,342A Expired CA1050426A (fr) 1975-09-26 1976-09-16 Procede de production d'un compose pharmaceutique d'insuline utilise par voie rectale

Country Status (8)

Country Link
AT (1) AT344327B (fr)
CA (1) CA1050426A (fr)
DE (1) DE2641819A1 (fr)
DK (1) DK431876A (fr)
FR (1) FR2325386A1 (fr)
GB (1) GB1563311A (fr)
NO (1) NO146044C (fr)
SE (1) SE7610595L (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6042766B2 (ja) * 1978-12-09 1985-09-25 日本化薬株式会社 基剤
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE2917535C2 (de) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Gegen Denaturierung beständige Insulinlösungen
EP0018609B1 (fr) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Solutions aqueuses de protéines, stables à la dénaturation, procédé pour leur fabrication et leur utilisation
EP0037943B1 (fr) 1980-03-31 1985-08-14 Teijin Limited Composition pharmaceutique pour administration rectale et suppositoire ainsi préparé
SU1011126A1 (ru) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Средство дл лечени сахарного диабета
AU558474B2 (en) * 1981-07-17 1987-01-29 Nordisk Insulinlaboratorium A stable aqueous, therapeutic insulin preparation and a process for preparing it
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
GB8417895D0 (en) * 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
JPH0651637B2 (ja) 1985-03-28 1994-07-06 エーザイ株式会社 ペプタイドの吸着防止組成物
US4760059A (en) * 1985-08-05 1988-07-26 Hoffmann-La Roche Inc. Rectal dosage form
WO2003003999A2 (fr) * 2001-07-02 2003-01-16 Elan Corporation, Plc. Distribution de matiere bioactive
JP4646669B2 (ja) 2005-03-30 2011-03-09 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、カートリッジ及び吐出装置
JP5605760B2 (ja) * 2010-01-18 2014-10-15 セイコーエプソン株式会社 吐出用液体、生体試料の吐出方法、及び化合物

Also Published As

Publication number Publication date
DK431876A (da) 1977-03-27
AT344327B (de) 1978-07-10
ATA713376A (de) 1977-11-15
NO146044C (no) 1982-08-04
FR2325386B1 (fr) 1979-01-12
SE7610595L (sv) 1977-03-27
GB1563311A (en) 1980-03-26
FR2325386A1 (fr) 1977-04-22
NO146044B (no) 1982-04-13
DE2641819A1 (de) 1977-04-07
NO763296L (fr) 1977-03-29

Similar Documents

Publication Publication Date Title
CA1050426A (fr) Procede de production d'un compose pharmaceutique d'insuline utilise par voie rectale
US5869090A (en) Transdermal delivery of dehydroepiandrosterone
US5521166A (en) Antiprogestin cyclophasic hormonal regimen
Gaspard Metabolic effects of oral contraceptives
WEXLER et al. Effects of a bacterial polysaccharide (Piromen®) on the pituitary-adrenal axis: adrenal ascorbic acid, cholesterol and histologic alterations
IE65864B1 (en) Treatment of postmenopausal disorders
ZORRILLA et al. Severe endogenous hypertriglyceridemia during treatment with estrogen and oral contraceptives
EP0242643A2 (fr) Administration nasale de médicaments
DE102005034498A1 (de) Orale Kontrazeption mit Trimegeston
PAULSEN et al. Inherent estrogenicity of norethindrone and norethynodrel: comparison with other synthetic progestins and progesterone
AP1171A (en) Hormonal composition consisting of an oestrogen compound and of a progestational compound.
KR100623788B1 (ko) 호르몬 조성물 및 이의 용도
CA2148357A1 (fr) Utilisation de 17.alpha.-dihydroequilenine pour abaisser la cholesterolemie
Burkman Jr et al. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate
Clarkson et al. Gonadal hormone substitutes: effects on the cardiovascular system
EP0662324A1 (fr) Utilisation d'agonistes bêta-adrénergiques pour le traitement des pertes de fonction des muscles striés
Martin et al. Preparations for menopausal hormone therapy
JP2000515889A (ja) プロゲスチンとエストロゲンとの混合剤からなる二相性避妊法およびキット
US5719137A (en) Method of preventing neurodegeneration and cognitive dysfunction using 17α-dihydroequilenin
Brock et al. Hepatic morphine and estrone glucuronyltransferase activity and morphine biliary excretion in the isolated perfused rat liver. Effect of pregnancy and estradiol-17 beta treatment.
WO1999051214A2 (fr) Kit contraceptif base uniquement sur la progestogene
WO1995005828A1 (fr) Composes a action antagoniste de la progesterone et anti-×strogene pour la therapie de liomyomes uterins
Dodds Synthetic æstrogens
US20230113311A1 (en) Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy
US20240173334A1 (en) Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy